Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2020655 | 1.00 | FAAH (0.36) | FAAHCNR2GRIK2ADAM17HSD11B1 | |
| SCHEMBL1168251 | 0.86 | HSD11B1 (0.45) | FAAHCNR2GRIK2ADAM17HSD11B1 | |
| SCHEMBL946220 | 0.77 | HSD11B1 (0.47) | FAAHCNR2GRIK2HSD11B1CYP11B1 | |
| SCHEMBL1168372 | 0.75 | FAAH (0.52) | FAAHCNR2GRIK2ADAM17HSD11B1 | |
| SCHEMBL1168472 | 0.74 | HSD11B1 (0.49) | FAAHCNR2HSD11B1KMT2A | |
| SCHEMBL3634002 | 0.72 | THRB (0.51) | FAAHHSD11B1NR1H4KMT2A | |
| SCHEMBL1169240 | 0.68 | MEN1 (0.51) | FAAHCNR2HSD11B1KMT2A | |
| SCHEMBL14135317 | 0.68 | FAAH (0.45) | FAAHCNR2GRIK2ADAM17NR1H4 | |
| SCHEMBL1168079 | 0.67 | HSD11B1 (0.45) | FAAHCNR2ADAM17HSD11B1NR1H4 | |
| SCHEMBL946055 | 0.66 | MAPK8 (0.49) | FAAHCNR2HSD11B1IDH1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | US | claimed |
| US-8507493-B2 | Amide and amidine derivatives and uses thereof | ABBVIE INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2243479-A2 | Novel amide and amidine derivates and uses thereof | Abbott Laboratories (US) | 2010-10-27 | — | — | EP | disclosed |
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | HSD11B2, HSD11B1, HSD17B2 | FAAH 72/4885CNR2 849/4885GRIK2 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.